FDA asks for more time to evaluate Onglyza for approval

04/24/2009 | Reuters

The FDA delayed by three months its approval decision on Onglyza, an experimental diabetes drug from AstraZeneca and Bristol-Myers Squibb. The agency said it needs more time to review Onglyza, although a spokesman for Bristol-Myers said he was not aware of any request from the agency for additional data on the product.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA